NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
View the latest financials